SCHEMBL252279

SCHEMBL252279

OCC1COC(CO)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL15993555 0.84 ALDH1A1 (0.33)
SCHEMBL11153107 0.83
Domiodol SCHEMBL11633809 0.83
SCHEMBL13455763 0.83
SCHEMBL4864294 0.83
SCHEMBL12535579 0.83
SCHEMBL9172771 0.83
Domiodol SCHEMBL19352 0.83
SCHEMBL9181813 0.83
SCHEMBL10817323 0.80 ALDH1A1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240082417-A1 PROTEIN-POLYMER DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2024-03-14 US claimed
EP-4302782-A2 NAPI2B-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF Mersana Therapeutics, Inc. (US) 2024-01-10 EP claimed
EP-3641826-B1 METHODS OF PRODUCING DRUG-CARRYING POLYMER SCAFFOLDS AND PROTEIN-POLYMER-DRUG CONJUGATES MERSANA THERAPEUTICS INC (US) 2023-12-06 EP claimed
US-20230338569-A1 NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER MERSANA THERAPEUTICS, INC. 2023-10-26 US claimed
US-20230312747-A1 Compositions and Methods for Treating Cancer SEAGEN INC. (US) 2023-10-05 US claimed
EP-3429693-B1 NAPI2B-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF MERSANA THERAPEUTICS INC (US) 2023-08-23 EP claimed
EP-3157959-B1 MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF MERSANA THERAPEUTICS INC (US) 2023-08-02 EP claimed
US-20230183326-A1 PROTEIN-POLYMER-DRUG CONJUGATES ASANA BIOSCIENCES, LLC 2023-06-15 US claimed
WO-2023039512-A1 NAPI2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER MERSANA THERAPEUTICS, INC. (US) 2023-03-16 WO claimed
EP-3475284-B1 PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF MERSANA THERAPEUTICS INC (US) 2022-11-02 EP claimed
WO-2011116026-A2 INHIBITORS OF BETA INTEGRIN-G PROTEIN ALPHA SUBUNIT BINDING INTERACTIONS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2011-09-22 WO claimed
EP-2349341-A2 PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES Baxter Healthcare SA (CH) 2011-08-03 EP claimed
EP-1667726-B1 POLYACETAL DRUG CONJUGATES AS RELEASE SYSTEM GEN HOSPITAL CORP (US) 2011-05-04 EP claimed
US-20110059010-A1 DUAL PHASE DRUG RELEASE SYSTEM THE GENERAL HOSPITAL CORPORATION (US) 2011-03-10 US claimed
US-20110028693-A1 BLOOD COAGULATION PROTEIN CONJUGATES BAXTER INTERNATIONAL INC. (US) 2011-02-03 US claimed
WO-2010045321-A2 PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES BAXTER INTERNATIONAL INC. (US) 2010-04-22 WO claimed
US-20100093934-A1 PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES BAXTER INTERNATIONAL INC. (US) 2010-04-15 US claimed
US-6822086-B1 HAVING REVERSIBLE ASSOCIATIONS; FOR DRUG SCREENING/TARGETING THE GENERAL HOSPITAL CORPORATION 2004-11-23 US claimed
EP-1206285-A2 DRUG-CARRIER COMPLEXES AND METHODS OF USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2002-05-22 EP claimed
WO-2001010468-A2 DRUG-CARRIER COMPLEXES AND METHODS OF USE THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2001-02-15 WO claimed